Together, these results demonstrate that selective pharmacological inhibition of HDAC1/2 is sufficient to mediate synergistic anti-cancer activity in combination with azacitidine in preclinical models of AML. This evidence concerns the gene HDAC1 and acute myeloid leukemia.